Partner
John Maraganore
Venture Partner, Entrée Bio, Entrée Capital (+1 more)
- Firm
- Entrée Capital, Omega Funds
- Title
- Venture Partner, Entrée Bio
- Role
- Venture partner
- Known as
- Investor
Claim, correct or request removal
Record updated 19 September 2026
About
John Maraganore is a pioneering biotech executive and scientist was the founding CEO of Alnylam Pharmaceuticals, which he led from 2002-2021. Alnylam advanced RNA interference (RNAi) from discovery to approval and commercialization of five RNAi medicines and grew to over $25B in market cap. Earlier, he held senior roles at Millennium Pharmaceuticals and Biogen, where he invented and led the development of ANGIOMAX®. John now leads JMM Innovations, serves on the boards of Takeda, Beam, Kymera, and Rapport. He holds M.S. and Ph.D. degrees in biochemistry and molecular biology from the University of Chicago.
Is this you? Remove my profile
Loading relationship preview